Mumbai: Drugmaker

孟买：制药商

Natco Pharma

纳特科制药

has said it will price its rare disease drug

表示将为其罕见病药物定价

Risdiplam

利司扑兰

used to treat spinal muscular atrophy at ₹15,900 per bottle, against ₹6.2 lakh per bottle charged by its innovator Swiss drugmaker

用于治疗脊髓性肌萎缩症，每瓶售价 ₹15,900，而瑞士创新药企每瓶收费 ₹62 万。

Roche

罗氏

under the brand

在品牌下

Evrysdi

艾满欣

.

。

However, the launch of the

然而，启动时

Natco

纳特科

drug has been put on hold by an appellate bench of the Delhi High Court, Natco informed. Natco had challenged Roche's patent validity in

药物已被德里高等法院的上诉委员会暂停，纳特科公司表示。纳特科曾对罗氏的专利有效性提出质疑。

India

印度

for the drug.

针对该药物。

Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche sells Risdiplam on a discounted basis or one bottle free for each bottle purchased.

每瓶Risdiplam大约能使用12天，患者每月的费用将约为₹30,000。消息人士称，罗氏公司以折扣价销售Risdiplam，或买一瓶赠送一瓶。

In March, a single bench had denied Roche's plea for an injunction against Natco's launch.

今年3月，一个单独的法官席驳回了罗氏公司要求禁止纳特科公司上市的请求。

Natco said it has now received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market.

纳科表示，目前已收到投资者和患者关于利西普兰仿制药在印度市场上市、供应和定价的大量咨询。

Live Events

现场活动

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)